in this issue
Regions :: Western Europe :: U.K.
Kyowa Hakko Kirin subsidiary to acquire Archimedes Pharma
July 12, 2014 | Natasha Alperowicz
Kyowa Hakko Kirin’s (KHK; Tokyo) subsidiary ProStrakan Group (Galashiels, UK) has agreed with Novo to purchase the entire share capital of Archimedes Pharma (Reading, UK) for £230 million ($393.8 million) in cash. Archimedes is a fast-growing, Europe-based specialty pharmaceutical company providing novel and advanced treatments within the therapeutic areas of pain, oncology, and critical care. Its largest product is PecFent, a nasal spray used to manage breakthrough cancer pain in patients who are already receiving maintenance opioid therapy for...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee